The Effect of Mindfulness-based Relapse Prevention on Impulsive Control Circuit Among Methamphetamine Dependents
NCT ID: NCT03748875
Last Updated: 2020-01-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
200 participants
INTERVENTIONAL
2020-05-01
2022-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Dose Response of Mirtazapine to Methamphetamine Induced Interest, Mood Elevation and Reward
NCT00600145
Behavioral Effects of Drugs (Inpatient): 40 [Methamphetamine, Methylphenidate, Duloxetine]
NCT04178993
Dopamine and Opioid Receptor Antagonists Reduce Cue-induced Reward Responding and Reward Impulsivity
NCT02557984
Amantadine for the Treatment of Traumatic Brain Injury Irritability and Aggression: A Multi-site Study
NCT00779324
Stanford Regulating Circuits of the Brain Study- Ketamine
NCT03475277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
an 8-session mindfulness-based relapse prevention program
mindfulness-based relapse prevention
mindfulness-based relapse prevention, 8 weeks
Control group
treatment as usual
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mindfulness-based relapse prevention
mindfulness-based relapse prevention, 8 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Comply with DSM-V diagnostic criteria for amphetamine-based addiction;
* The previous use of amphetamines for not less than 1 year (at least once a week);
* Vision and hearing are normal, or in the normal range after correction. No contraindications for magnetic resonance imaging;
* agree to cooperate with the completion of follow-up evaluation;
* The Mindfulness Attention Awareness Scale score is greater than 50 points.
Exclusion Criteria
* There have been other abuse or dependence of psychoactive substances in the past 5 years (excluding nicotine); 100 healthy controls have been publicly collected by the public. Exclude serious physical illness and mental damage. through
* SCID clinical interviews exclude family history of mental disorders and psychosis, no history of substance abuse (except nicotine).
18 Years
45 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai Mental Health Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
JDu-006
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.